Tyrogenex 
Welcome,         Profile    Billing    Logout  
 1 Product   34 Diseases  1 Product   18 Trials   223 News 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fumena (vorolanib) / Tyrogenex
CONCEPT study, NCT03095040: CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

Active, not recruiting
3
390
RoW
CM082 combined with everolimus, X-82, Affinitor, CM082, Everolimus
AnewPharma
Renal Cell Cancer Metastatic
02/21
12/21
NCT04373369: Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Active, not recruiting
2
11
US
Vorolanib, X-82, Atezolizumab, Tecentriq
Washington University School of Medicine, Xcovery Holdings, Inc.
Extensive-stage Small Cell Lung Cancer
08/22
07/25
AK104-SCLC-01, NCT06406673: A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer

Recruiting
2
70
RoW
Cadonilimab+EC/ET+RT, Cadonilimab+vorolanib
Henan Cancer Hospital
Extensive Small Cell Lung Cancer
08/24
12/24
NCT05383209: Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

Completed
2
77
US
EYP-1901, Vorolanib, Sham IVT
EyePoint Pharmaceuticals, Inc.
Nonproliferative Diabetic Retinopathy
02/24
05/24
VORSIN-RCC, NCT06523049: Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

Not yet recruiting
2
67
RoW
Vorolanib Tablets, Vorolanib, Sintilimab Injection, Sintilimab
Hao Zeng
Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy
07/26
09/26
Vigor, NCT06728852: Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study

Recruiting
2
32
RoW
Administration of Vorolanib
Li-kun Chen
Advanced Non-small Cell Lung Cancer (NSCLC), Recurrent or Metastatic Lung Cancer, Third-line and Beyond Therapy, Angiogenesis Inhibition in Oncology
12/26
12/26
VERONA, NCT06099184: Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Completed
2
27
US
EYP-1901, Vorolanib, Aflibercept 2Mg/0.05Ml Inj,Oph, Eylea
EyePoint Pharmaceuticals, Inc.
Diabetic Macular Edema
10/24
10/24
NCT07047001: Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma

Active, not recruiting
2
60
RoW
Vorolanib Tablets, CM082, Vorolanib + Toripalimab, Toripalimab: JS001, Vorolanib:CM082
Dong Wen
Renal Cell Carcinoma (RCC), Adjuvant
06/29
06/32
ChiCTR2400084978: An open-label, phase II cohort study of vorolanib combined with other therapies in patients with soft tissue sarcoma who have failed first-line or higher-level standard therapy

Not yet recruiting
2
68
 
vorolanib combined with chemotherapy; vorolanib combined with epigenetic drugs
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, Betta Pharmaceuticals Co., Ltd.
soft tissue sarcoma
 
 
ChiCTR2500101139: Efficacy and safety of Vorolanib in patients with inoperable progressive or symptomatic desmoid tumors:A prospective, single-arm, phase II study

Recruiting
2
18
 
Based on Simon two-stage optimal design, 5 patients are planned to be enrolled in the first stage and 13 patients are planned to be enrolled in the second stage. Vorolanib Tablets will be administered once daily at a dose of 200 mg. The dose can be reduced by one level to 100 mg or the drug can be permanently discontinued based on the type and grade of specific adverse effects. Vorolanib treatment will continue until disease progression or the occurrence of intolerable toxic and side effects, with a maximum duration of one year.
West China Hospital, Sichuan University; West China Hospital, Sichuan University, None
desmoid tumor
 
 
ChiCTR2500101854: Efficacy and Safety of Vorolanib Monotherapy or in Combination with Toripalimab as Adjuvant Therapy for Intermediate-High Risk Early-Stage/Mid-Stage Renal Cancer Patients After Surgery: A Multicenter, Randomized, Double-Arm, Phase II Exploratory Study.

Recruiting
2
60
 
Vorolanib 100 mg QD combined with toripalimab 240 mg Q3W.; Vorolanib 200 mg QD.
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Corporate sponsorship / Betta Pharmaceuticals Co., Ltd. Junshi Biosciences Co., Ltd.
Localized or locally advanced renal clear cell carcinoma with intermediate-high risk of recurrence.
 
 
CA209-982, NCT03583086: Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Completed
1/2
88
US
Vorolanib, Nivolumab
Vanderbilt-Ingram Cancer Center, Bristol-Myers Squibb, Xcovery Holdings, Inc.
Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer
02/24
04/24
NCT06577961: Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients

Not yet recruiting
1/2
37
NA
Vorolanib, CM082, cadonilimab, AK104
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Kidney Cancer, RCC, Renal Cell Carcinoma
08/27
08/27
ChiCTR2500103324: A prospective, single-arm phase I/II clinical study of befotertinib in combination with vorolanib neoadjuvant in patients with stage II-IIIB EGFR-positive non-small cell lung cancer

Not yet recruiting
1/2
39
 
All enrolled patients received 2 cycles (42 days) of neoadjuvant befotertinib in combination with vorolanib
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, Betta Pharmaceuticals Co., Ltd.
non-small cell lung cancer
 
 
ChiCTR2400086552: Study on the Efficacy and Safety of Vorolanib Combined with Cadonilimab in the Treatment of Untreated Advanced RCC Patients

Not yet recruiting
1/2
37
 
Vorolanib combined with cadonilimab
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, Betta Pharmaceuticals Co., Ltd.
Kidney Cancer
 
 
ChiCTR-IID-17013889: Phase I clinical trial of the safety, tolerability, pharmacokinetics and initial efficacy of CM082 in the treatment of wet age-related macular degeneration (wAMD)

Completed
1
108
 
25mg dose ;50mg dose ;75mg dose ;100mg dose
Beijing Tongren Hospital, Capital Medical University; Beijing Tongren Hospital, Capital Medical University, Kananji Medical Technology (Shanghai) Co., Ltd.
wet age-related macular degeneration
 
 
NCT03792958: Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors

Active, not recruiting
1
19
RoW
CM082, X-82
AnewPharma, Shanghai East Hospital
Advanced Malignant Solid Tumors
06/23
06/23
NCT06585878: A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma

Not yet recruiting
N/A
60
NA
Stereotactic Ablative Radiotherapy (SABR)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Renal Cell Carcinoma, RCC, Kidney Cancer
04/27
04/27
NCT06676527: Vorolanib in the Second-line Treatment of Patients with Unresectable or Metastatic Renal Cell Carcinoma

Recruiting
N/A
39
RoW
Follow-up study of the treated cohort
Jinling Hospital, China
Neoplasms, Kidney Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases, Urogenital Diseases, Kidney Diseases, Urologic Diseases, Carcinoma, Renal Cell Cancer, Carcinoma, Renal Cell, Antineoplastic Agents
09/26
09/26
ChiCTR2400080233: The exploration of Vorolanib combined with chemotherapy in the first-line treatment of ES-SCLC

Not yet recruiting
N/A
40
 
Induction treatment period (4 cycles, 21 days a cycle) : vorolanib initiator 100 mg QD, after enrolling 3 patients without SAE, add to 200mg QD; Cisplatin 75 mg/m2 d1-3,and Etoposide 100 mg/m2 d1-3 were given intravenously. Maintenance treatment period: vorolanib 200MG/d, oral, until the disease progression.
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Betta Pharmaceuticals Co., Ltd.
lung cancer
 
 
X-414 / Tyrogenex
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fumena (vorolanib) / Tyrogenex
CONCEPT study, NCT03095040: CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

Active, not recruiting
3
390
RoW
CM082 combined with everolimus, X-82, Affinitor, CM082, Everolimus
AnewPharma
Renal Cell Cancer Metastatic
02/21
12/21
NCT04373369: Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Active, not recruiting
2
11
US
Vorolanib, X-82, Atezolizumab, Tecentriq
Washington University School of Medicine, Xcovery Holdings, Inc.
Extensive-stage Small Cell Lung Cancer
08/22
07/25
AK104-SCLC-01, NCT06406673: A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer

Recruiting
2
70
RoW
Cadonilimab+EC/ET+RT, Cadonilimab+vorolanib
Henan Cancer Hospital
Extensive Small Cell Lung Cancer
08/24
12/24
NCT05383209: Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

Completed
2
77
US
EYP-1901, Vorolanib, Sham IVT
EyePoint Pharmaceuticals, Inc.
Nonproliferative Diabetic Retinopathy
02/24
05/24
VORSIN-RCC, NCT06523049: Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

Not yet recruiting
2
67
RoW
Vorolanib Tablets, Vorolanib, Sintilimab Injection, Sintilimab
Hao Zeng
Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy
07/26
09/26
Vigor, NCT06728852: Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study

Recruiting
2
32
RoW
Administration of Vorolanib
Li-kun Chen
Advanced Non-small Cell Lung Cancer (NSCLC), Recurrent or Metastatic Lung Cancer, Third-line and Beyond Therapy, Angiogenesis Inhibition in Oncology
12/26
12/26
VERONA, NCT06099184: Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Completed
2
27
US
EYP-1901, Vorolanib, Aflibercept 2Mg/0.05Ml Inj,Oph, Eylea
EyePoint Pharmaceuticals, Inc.
Diabetic Macular Edema
10/24
10/24
NCT07047001: Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma

Active, not recruiting
2
60
RoW
Vorolanib Tablets, CM082, Vorolanib + Toripalimab, Toripalimab: JS001, Vorolanib:CM082
Dong Wen
Renal Cell Carcinoma (RCC), Adjuvant
06/29
06/32
ChiCTR2400084978: An open-label, phase II cohort study of vorolanib combined with other therapies in patients with soft tissue sarcoma who have failed first-line or higher-level standard therapy

Not yet recruiting
2
68
 
vorolanib combined with chemotherapy; vorolanib combined with epigenetic drugs
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, Betta Pharmaceuticals Co., Ltd.
soft tissue sarcoma
 
 
ChiCTR2500101139: Efficacy and safety of Vorolanib in patients with inoperable progressive or symptomatic desmoid tumors:A prospective, single-arm, phase II study

Recruiting
2
18
 
Based on Simon two-stage optimal design, 5 patients are planned to be enrolled in the first stage and 13 patients are planned to be enrolled in the second stage. Vorolanib Tablets will be administered once daily at a dose of 200 mg. The dose can be reduced by one level to 100 mg or the drug can be permanently discontinued based on the type and grade of specific adverse effects. Vorolanib treatment will continue until disease progression or the occurrence of intolerable toxic and side effects, with a maximum duration of one year.
West China Hospital, Sichuan University; West China Hospital, Sichuan University, None
desmoid tumor
 
 
ChiCTR2500101854: Efficacy and Safety of Vorolanib Monotherapy or in Combination with Toripalimab as Adjuvant Therapy for Intermediate-High Risk Early-Stage/Mid-Stage Renal Cancer Patients After Surgery: A Multicenter, Randomized, Double-Arm, Phase II Exploratory Study.

Recruiting
2
60
 
Vorolanib 100 mg QD combined with toripalimab 240 mg Q3W.; Vorolanib 200 mg QD.
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Corporate sponsorship / Betta Pharmaceuticals Co., Ltd. Junshi Biosciences Co., Ltd.
Localized or locally advanced renal clear cell carcinoma with intermediate-high risk of recurrence.
 
 
CA209-982, NCT03583086: Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Completed
1/2
88
US
Vorolanib, Nivolumab
Vanderbilt-Ingram Cancer Center, Bristol-Myers Squibb, Xcovery Holdings, Inc.
Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer
02/24
04/24
NCT06577961: Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients

Not yet recruiting
1/2
37
NA
Vorolanib, CM082, cadonilimab, AK104
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Kidney Cancer, RCC, Renal Cell Carcinoma
08/27
08/27
ChiCTR2500103324: A prospective, single-arm phase I/II clinical study of befotertinib in combination with vorolanib neoadjuvant in patients with stage II-IIIB EGFR-positive non-small cell lung cancer

Not yet recruiting
1/2
39
 
All enrolled patients received 2 cycles (42 days) of neoadjuvant befotertinib in combination with vorolanib
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, Betta Pharmaceuticals Co., Ltd.
non-small cell lung cancer
 
 
ChiCTR2400086552: Study on the Efficacy and Safety of Vorolanib Combined with Cadonilimab in the Treatment of Untreated Advanced RCC Patients

Not yet recruiting
1/2
37
 
Vorolanib combined with cadonilimab
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, Betta Pharmaceuticals Co., Ltd.
Kidney Cancer
 
 
ChiCTR-IID-17013889: Phase I clinical trial of the safety, tolerability, pharmacokinetics and initial efficacy of CM082 in the treatment of wet age-related macular degeneration (wAMD)

Completed
1
108
 
25mg dose ;50mg dose ;75mg dose ;100mg dose
Beijing Tongren Hospital, Capital Medical University; Beijing Tongren Hospital, Capital Medical University, Kananji Medical Technology (Shanghai) Co., Ltd.
wet age-related macular degeneration
 
 
NCT03792958: Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors

Active, not recruiting
1
19
RoW
CM082, X-82
AnewPharma, Shanghai East Hospital
Advanced Malignant Solid Tumors
06/23
06/23
NCT06585878: A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma

Not yet recruiting
N/A
60
NA
Stereotactic Ablative Radiotherapy (SABR)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Renal Cell Carcinoma, RCC, Kidney Cancer
04/27
04/27
NCT06676527: Vorolanib in the Second-line Treatment of Patients with Unresectable or Metastatic Renal Cell Carcinoma

Recruiting
N/A
39
RoW
Follow-up study of the treated cohort
Jinling Hospital, China
Neoplasms, Kidney Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases, Urogenital Diseases, Kidney Diseases, Urologic Diseases, Carcinoma, Renal Cell Cancer, Carcinoma, Renal Cell, Antineoplastic Agents
09/26
09/26
ChiCTR2400080233: The exploration of Vorolanib combined with chemotherapy in the first-line treatment of ES-SCLC

Not yet recruiting
N/A
40
 
Induction treatment period (4 cycles, 21 days a cycle) : vorolanib initiator 100 mg QD, after enrolling 3 patients without SAE, add to 200mg QD; Cisplatin 75 mg/m2 d1-3,and Etoposide 100 mg/m2 d1-3 were given intravenously. Maintenance treatment period: vorolanib 200MG/d, oral, until the disease progression.
Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Betta Pharmaceuticals Co., Ltd.
lung cancer
 
 
X-414 / Tyrogenex
No trials found

Download Options